^
Association details:
| Biomarker: | BRCA1 deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Published date:
05/27/2021
Excerpt:
BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion...Overall, APCs with homozygous BRCA2 deletion are exceptional responders...
DOI:
10.1158/2159-8290.CD-21-0007
Source:
Title:
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Published date:
08/14/2020
Excerpt:
The overall efficacy population included 115 patients who received ≥ 1 dose of rucaparib and had a deleterious BRCA alteration (BRCA1 [n = 13]….The confirmed ORR for the IRR-evaluable population was 43.5% (95% CI, 31.0% to 56.7%; 27 of 62), and the confirmed ORR for the investigator-evaluable population was 50.8%...In the IRR- and investigator-evaluable populations, 64.5% and 63.1% of patients demonstrated a ≥ 30% reduction in target lesion size from baseline….Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration…
DOI:
10.1200/JCO.20.01035
Source:
Title:
Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).
Published date:
02/14/2020
Excerpt:
A biallelic alteration was observed in 81.4% (35/43) of BRCA pts for whom zygosity could be determined, and pts with homozygous BRCA loss (20.4%; 20/98) demonstrated high ORR (66.7% [95% CI, 38.4-88.2]; 10/15) and PSA response rates (75.0% [95% CI, 50.9-91.3]; 15/20).
Trial ID:
Source:
Title:
Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
Published date:
10/01/2018
Excerpt:
Rucaparib has encouraging antitumour activity in mCRPC pts with a deleterious alteration in BRCA1 or BRCA2. Updated data from current and newly enrolled pts will be presented, including from pts with other gene alterations.
DOI:
10.1093/annonc/mdy284.002
Trial ID:
